Changes in health-related quality of life with smoking cessation treatment

James Taylor Hays, Ivana T Croghan, Christine L. Baker, Joseph C. Cappelleri, Andrew G. Bushmakin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.

Original languageEnglish (US)
Pages (from-to)224-229
Number of pages6
JournalEuropean Journal of Public Health
Volume22
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Health Transition
Withholding Treatment
Bupropion
Smoking Cessation
Quality of Life
Smoking
Placebos
Tobacco Use Disorder
Therapeutics
Tobacco Products
Anxiety
Randomized Controlled Trials
Self-Control
Varenicline
Health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Changes in health-related quality of life with smoking cessation treatment. / Hays, James Taylor; Croghan, Ivana T; Baker, Christine L.; Cappelleri, Joseph C.; Bushmakin, Andrew G.

In: European Journal of Public Health, Vol. 22, No. 2, 04.2012, p. 224-229.

Research output: Contribution to journalArticle

Hays, James Taylor ; Croghan, Ivana T ; Baker, Christine L. ; Cappelleri, Joseph C. ; Bushmakin, Andrew G. / Changes in health-related quality of life with smoking cessation treatment. In: European Journal of Public Health. 2012 ; Vol. 22, No. 2. pp. 224-229.
@article{33fc11e191d74fb6af7015912f81ea21,
title = "Changes in health-related quality of life with smoking cessation treatment",
abstract = "Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.",
author = "Hays, {James Taylor} and Croghan, {Ivana T} and Baker, {Christine L.} and Cappelleri, {Joseph C.} and Bushmakin, {Andrew G.}",
year = "2012",
month = "4",
doi = "10.1093/eurpub/ckq137",
language = "English (US)",
volume = "22",
pages = "224--229",
journal = "European Journal of Public Health",
issn = "1101-1262",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Changes in health-related quality of life with smoking cessation treatment

AU - Hays, James Taylor

AU - Croghan, Ivana T

AU - Baker, Christine L.

AU - Cappelleri, Joseph C.

AU - Bushmakin, Andrew G.

PY - 2012/4

Y1 - 2012/4

N2 - Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.

AB - Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.

UR - http://www.scopus.com/inward/record.url?scp=84859792880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859792880&partnerID=8YFLogxK

U2 - 10.1093/eurpub/ckq137

DO - 10.1093/eurpub/ckq137

M3 - Article

C2 - 20884658

AN - SCOPUS:84859792880

VL - 22

SP - 224

EP - 229

JO - European Journal of Public Health

JF - European Journal of Public Health

SN - 1101-1262

IS - 2

ER -